The Claim

Among Medicare Advantage beneficiaries with type 2 diabetes and established atherosclerotic cardiovascular disease, initiating glucagon-like peptide-1 receptor agonists compared to initiating sodium-glucose cotransporter-2 inhibitors is associated with 8.9% higher pharmacy costs and no significant difference in medical costs, hospitalizations, or emergency department visits.

Source: Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
67score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In older adults with type 2 diabetes and heart disease, starting GLP-1 RA drugs leads to 8.9% higher drug costs than starting SGLT2i drugs, with no difference in hospital visits, emergency room use, or other medical expenses.

See the scientific wording

Among Medicare Advantage beneficiaries with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), initiating glucagon-like peptide-1 receptor agonists (GLP-1 RA) is associated with 8.9% higher pharmacy costs but no significant difference in medical costs, hospitalizations, or emergency department visits compared to initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i), indicating that higher drug costs are not offset by reduced acute care use in this high-risk subgroup.

Why this might work

GLP-1 receptor agonists make the pancreas release more insulin and block the release of glucagon, which lowers blood sugar but requires expensive drugs. This does not stop the buildup of plaque in arteries or prevent heart attacks and strokes, so hospital visits and emergency care stay the same.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.

    In older adults with diabetes and heart disease, GLP-1 RA drugs cost more than SGLT2i drugs, but people on GLP-1 RAs don’t go to the hospital or ER more often — so the higher drug price isn’t saved by fewer medical visits.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.